We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Keystone Investment Trust Plc | LSE:KIT | London | Ordinary Share | GB00BK96BB68 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 339.00 | 338.00 | 340.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/10/2020 10:49 | Had a few this morning. | essentialinvestor | |
06/10/2020 01:28 | Have a look at eua if not already in. Multi bagger... under negotiations to sell whole company or an asset. News due soon. | easwarareddy | |
09/9/2020 16:46 | 17% of the portfolio is gold miners Barrick Gold the biggest holding at 6.3% Warren Buffet bought a big stake in Barrick very recently. This trust continues to look cheap on a big discount. | orinocor | |
09/9/2020 12:43 | That was an error, they're showing update for end July. | poikka | |
03/9/2020 17:55 | Wow, KIT are really ahead of the game - just announced the portfolio update for 30th June. Been on holiday, have you? | poikka | |
30/6/2020 12:56 | The discount has widened again to 18% based on the buy price of 248p and todays NAV announcement of 303p | orinocor | |
22/6/2020 17:26 | If the KIT board are serious about narrowing the discount they need to introduce a continuation vote at the AGM, say, every 3 years. Or maybe tender offers at NAV minus 5% ? | emptyglass | |
19/6/2020 19:42 | The last 3 days the company has bought back 1% of the company's shares. | orinocor | |
17/6/2020 09:29 | The UK focussed trusts such as ASEI,EDIN, PLI, TMPL, IVI are now on NAV discounts of under 10% whereas KIT is on a 15% discount. I bought some more at 153p just now, under the mid price. | orinocor | |
10/6/2020 12:09 | NAV down to 310p. I bought some more at 250.5p for a 19% discount. Weird. The quoted price is misleading. The buy price is nearly the same as the displayed sell price | orinocor | |
09/6/2020 15:48 | NAV 316.5p I bought some more just now at 254p for a >19% discount. That's before accounting for today's market drop. Hoping the 15% gold weighting will cushion falls in the wider market. Still the best value general IT for me. | orinocor | |
08/6/2020 11:28 | NAV 314p 16% discount | orinocor | |
05/6/2020 13:42 | This rally just keeps going. ftse +109 points | orinocor | |
05/6/2020 08:36 | still 40% upside here to the january level | orinocor | |
05/6/2020 08:35 | Topped up with purchases at 250 and 254 this morning. Yesterdays NAV was 309.5p so Kit is on a 17% discount even if you pay full ask of 257p That compares well with the mighty Edin which is on a 11.5% discount | orinocor | |
28/5/2020 12:36 | NAV 299.3p | orinocor | |
14/5/2020 20:24 | The Company’s objective is to provide shareholders with long-term growth of capital, mainly from UK investments. | orinocor | |
14/5/2020 20:02 | THAT'S WHAT "I'M GETTING AT". GOT IT! ILL-MANNERED SOD. | poikka | |
14/5/2020 20:01 | Thought I made it clear enough, but here goes: holding reliable divi payers alongside a growth portfolio. Pharmas should be inflation-proof, AND be growth stocks. Did I say ALL big yielders? No, I did not. | poikka | |
14/5/2020 19:48 | I'm not sure what you're getting at. It's easy enough to put all the big yielders in the portfolio and pay shareholders a big dividend but I don't think that's been very successful for some big ITs in recent years. | orinocor | |
14/5/2020 15:17 | Yesterdays NAV announced at 285p. Its going to be less by tomorrow but maybe not too bad compared to the rest of the market. The 4 gold miners, 15% of the portfolio, are up about 3% today on average. | orinocor | |
11/5/2020 13:48 | I missed the results last week but happy after reading through them. Pleased with 15% gold exposure and Goldstone makes a strong case. | orinocor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions